PolyPid Ltd. (PYPD)
NASDAQ: PYPDHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PYPD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $129.29M
- EPS (TTM)
- -$1.31
- Dividend yield
- None
- 52-week range
- 3.60 – 7.25
- Day range
- 6.09 – 6.76
- Volume / Avg
- 448.95K / 148.00K
- Beta
- —
- Shares outstanding
- 21.13M
52-week range
PYPD stock today
On Nov 20, PYPD ended the session at $6.12, shedding $0.43 (6.56%), versus the S&P 500's 3.70% decline. Volume was 3.0x the average at 448.95K shares, a sign of unusually heavy trading. Shares are 15.6% below their 52-week high of $7.25, set on Nov 19, 2026 and 70.0% above the 52-week low of $3.60, in the middle of the past year's range.
PYPD is up 41.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 70.0%. PolyPid has posted a net loss over the last twelve months (EPS of -$1.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PolyPid
Company profilePolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Ms. Dikla Czaczkes Akselbrad
- Headquarters
- Petah Tikva
- Employees
- 69
- IPO year
- 2020
- Website
- polypid.com
Financial highlights
Full financialsPolyPid reported a net loss of $34.2 million, compared with a loss of $29.0 million a year earlier. Diluted earnings per share came in at $2.09, down from $4.91.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-34.17M | $-29.02M | $-23.86M | $-39.56M | $-42.60M |
| EPS (diluted) | $2.09 | $4.91 | $16.93 | $61.09 | $68.27 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$11.50+87.91%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.24 vs $0.46
- Surprise
- -152.17%
PYPD news
All PYPD news- PolyPid Ltd. Reports Third Quarter 2026 Financial Results and Updates on D-PLEX₁₀₀ Regulatory ProgressNasdaq
- PolyPid: 3 Key Takeaways for Long-Term InvestorsNasdaq
- PolyPid Highlights D-PLEX100 Regulatory Progress, Reports Narrower Q3 Loss; Stock UpNasdaqPYPD, DDS
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Biotech Stocks Facing FDA Decision In November 2026NasdaqAGIO, BBIO, CAPR, COGT
- PolyPid Ltd. Introduces PD01B and Outlines D-PLEX₁₀₀ MilestonesNasdaq
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026GlobeNewswire
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026GlobeNewswire
PolyPid peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STIMNeuronetics Inc. | 1.25 | +0.81% | $120.60M | vs PYPD |
| KRMDKORU Medical Systems Inc. | 3.19 | -7.27% | $138.37M | vs PYPD |
| LUNGPulmonx Corporation | 2.57 | -6.20% | $111.93M | vs PYPD |
| APYXApyx Medical Corporation | 2.40 | +0.42% | $101.10M | vs PYPD |
| NYXHNyxoah SA | 0.805 | -7.01% | $81.98M | vs PYPD |
| ANIKAnika Therapeutics Inc. | 13.23 | -0.38% | $177.22M | vs PYPD |
| SKINSkinHealth Systems Inc. Class A | 11.77 | -3.13% | $76.68M | vs PYPD |
| LUCDLucid Diagnostics Inc. | 0.3727 | -3.52% | $72.57M | vs PYPD |
Indexes, lists and sector
PolyPid stock FAQ
What is PolyPid's stock price today?
PYPD last traded at $6.12 as of Nov 20, 4:00 PM EST, down 6.56% on the day. Prices are delayed at least 15 minutes.
Does PolyPid pay a dividend?
No. PolyPid does not currently pay a regular cash dividend.
Who is PolyPid's CEO?
Ms. Dikla Czaczkes Akselbrad is the chief executive officer of PolyPid Ltd., which has about 69 employees.
Has PYPD ever split its stock?
Yes. The most recent PYPD stock split was a 1-for-30 split on Sep 21, 2023.
What is the PYPD 52-week high?
The 52-week high for PYPD is $7.25 and the 52-week low is $3.60. The stock is currently 15.6% below its high.